



MATERIAL SAFETY DATA SHEET

Product Name: Mannitol Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Manufacturer Name
And Address** Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

Note: Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.

**Emergency Telephone
Hospira, Inc.** CHEMTREC: 800 424-9300
224 212-2055

Product Name Mannitol Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Mannitol
Chemical Formula C₆H₁₄O₆

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Mannitol	20	69-65-8	OP2060000
Water	80	7732-18-5	ZC0110000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used as an osmotic diuretic. Possible target organs include the kidneys and eyes.

**Occupational Exposure
Potential** Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data suggest the following: increased urine output, diarrhea, dry mouth, headaches, nausea, vomiting.

**Medical Conditions
Aggravated by Exposure** Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: eyes, kidneys

Product Name: Mannitol Injection, USP

4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable.

Fire & Explosion Hazard: None

Extinguishing Media: Use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required.

Storage No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).

Special Precautions Protect from freezing and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Mannitol	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established STEL: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Mannitol Injection, USP

Respiratory Protection Respiratory protection is not needed during normal product use.

Skin Protection If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.

Eye Protection Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.

Engineering Controls Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State Clear solution

Odor Odorless

Boiling Point Not Determined

Freezing Point Not Determined

Vapor Pressure Not Determined

Vapor Density (Air=1) Not Applicable

Evaporation Rate Not Determined

Bulk Density Not Determined

Specific Gravity 0.965-1.070 at 25°C

Solubility Water

pH 4.5– 7.0

10. STABILITY AND REACTIVITY

Chemical Stability Stable under standard use and storage conditions.

Incompatibilities A white flocculent precipitate may form if 25% Mannitol Injection is placed in contact with PVC surfaces

Hazardous Decomposition Products Toxic fumes of acrid smoke

Hazardous Polymerization Not Determined.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

Ingredient(s)	Percent	Test Type	Value	Units	Species
Mannitol	100	LD50	13,500-22,000	mg/kg	Mice, Rats

LD50 is the dosage producing 50% mortality.
Product contains approximately 20% Mannitol.

Mutagenicity Not Determined

Target Organ Effects In clinical use target organ effects include the kidneys.

Product Name: Mannitol Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status	Mannitol is listed on the TSCA inventory
CERCLA Status	Not Regulated
SARA Status	Not Regulated
RCRA Status	Not Regulated
PROP 65 (Calif.)	Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator T. Straits MPH, CIH
Date Prepared September 15, 2005

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.